BIAF stock forecast, quote, news & analysis
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI)... Show more
Why bioAffinity Technologies (BIAF) Stock Is Down -56% in the Last 30 Days
Key Takeaways
- BIAF shares declined roughly 56% over the 30-day window ending in mid-October 2026, sliding from about $7.95 to $3.51.
- The pullback extends a longer slide: the stock is down roughly 67% over the past quarter and about 85% over the past 52 weeks.
- Extreme swings reflect a low-float micro-cap, with roughly 540,000 shares outstanding following a 1-for-15 reverse split in late August 2026.
- bioAffinity remains pre-profitability, posting a wider net loss and negative cash flow while commercializing its single product, CyPath Lung.
- Elevated short interest and recurring reliance on equity financing add to share-count dilution and volatility risk.
bioAffinity Technologies (BIAF) Company Overview and Market Position
bioAffinity Technologies is a San Antonio, Texas-based biotechnology and diagnostics company focused on non-invasive testing for early-stage lung cancer and other pulmonary diseases. Its flagship commercial product, CyPath Lung, is a flow-cytometry-based laboratory developed test (LDT) designed to help clinicians detect early-stage lung cancer, and management has reported accelerating year-over-year growth in physician adoption and test volumes.
The company is also advancing companion diagnostics for asthma and chronic obstructive pulmonary disease (COPD) and has disclosed early-stage preclinical research into a therapeutic approach using small interfering RNAs (siRNAs). Shares trade on the Nasdaq Capital Market under the symbol BIAF. Investors follow the stock for its early-stage commercialization story, though the business remains highly dependent on a single commercial product.
bioAffinity Technologies (BIAF) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BIAF fell from a closing price of $7.95 on September 11, 2026 — the nearest prior trading session to 30 days earlier — to an intraday level near $3.51 in mid-October, a decline of roughly 56%. The move was not a straight line: after a brief spike in early September that carried the stock to an intraday high above $20, the shares gave back those gains and continued lower.
The quarterly picture is similarly weak. From a close of about $10.50 in mid-July to roughly $3.51 in mid-October, the stock lost about 67%. The longer-term trend is even more pronounced, with a 52-week decline of about 85% and the shares trading well below their 50-day and 200-day moving averages.
What Drove BIAF Stock Price in the Last 30 Days
Several verified factors shaped the sharp decline. First, bioAffinity completed a 1-for-15 reverse stock split in late August 2026, which reduced the outstanding share count to roughly 540,000 shares and created a very small public float of about 532,000 shares. Low-float micro-cap stocks are prone to outsized swings, and BIAF's trading reflected that dynamic across several sessions of unusually heavy volume.
Second, the company's fundamentals remain under pressure. bioAffinity is not yet profitable, reporting a wider net loss and negative operating cash flow as it invests in commercialization. Management has also disclosed a strategic discontinuation of certain lower-margin pathology services, which weighed on reported revenue. Third, the company continues to rely on equity financing — including a June 2026 public offering — which raises the risk of shareholder dilution. Elevated short interest of roughly 13% of shares outstanding and single-product concentration in CyPath Lung added further downward pressure on sentiment.
What Drove BIAF Stock Performance Over the Last Quarter
The quarterly decline reflects a broader multi-month repricing rather than a single event. In its first-quarter 2026 results reported in May, bioAffinity posted mixed financials: strong CyPath Lung growth of more than 200% year over year was offset by lower total revenue and a wider net loss. The reverse split and subsequent low-float dynamics amplified volatility, while continued capital raises, persistent operating losses, and regulatory uncertainty around laboratory developed tests kept investors cautious.
At the same time, the company advanced several long-term initiatives, including a Department of Defense-supported clinical trial and expanded development of asthma and COPD companion diagnostics. These programs signal a broader pipeline, but they have not yet offset near-term execution and funding concerns.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of top-performing AI trading bots from a platform that offers hundreds of bots trading thousands of tickers. Because only the most relevant and best-performing robots appear in this curated section, traders can quickly scan strategies that are currently gaining traction. The bots vary by strategy, timeframe, and performance metrics, so the page serves as a practical starting point for exploring automated approaches. For those looking to see which AI-driven strategies are attracting attention right now, the page is worth a closer look.
BIAF Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to monitor bioAffinity's next earnings report, estimated for mid-November 2026, for evidence of CyPath Lung volume growth and any progress toward narrowing losses. Other key factors include the pace of physician adoption and reimbursement expansion, results from the Department of Defense-supported trial, advancement of the asthma and COPD companion diagnostics, and any further capital-raising activity that could dilute shareholders. Regulatory developments governing laboratory developed tests, along with changes in short interest and float dynamics, could also influence near-term volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BIAF in -11.36% downward trend, sliding for three consecutive days on October 19, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BIAF declined for three days, in 289 of 314 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIAF as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Aroon Indicator for BIAF entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BIAF just turned positive on September 23, 2026. Looking at past instances where BIAF's MACD turned positive, the stock continued to rise in 27 of 34 cases over the following month. The odds of a continued upward trend are 79%.
BIAF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.569) is normal, around the industry mean (64.450). P/E Ratio (-2.644) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.229) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. BIAF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties